In The Global Politics of Pharmaceutical Monopoly Power, researcher and global advocate Ellen 't Hoen explains how new global rules for pharmaceutical patenting impact access to medicines in the developing world. The book gives an account of the current debates on intellectual property, access to medicines, and medical innovation, and provides historical context that explains how the current system emerged. This book supports major policy changes in the management of pharmaceutical patents and the way medical innovation is financed in order to protect public health and, in particular, promote access to essential medicines for all. The Open Society Institute provided support to translate this report into Russian.
During most of the nineteenth century, physicians and pharmacists alike considered medical patenting and the use of trademarks by drug manufacturers unethical forms of monopoly; physicians who prescribed patented drugs could be, and were, ostracized from the medical community. In the decades following the Civil War, however, complex changes in patent and trademark law intersected with the changing sensibilities of both physicians and pharmacists to make intellectual property rights in drug manufacturing scientifically and ethically legitimate. By World War I, patented and trademarked drugs had become essential to the practice of good medicine, aiding in the rise of the American pharmaceutical industry and forever altering the course of medicine. Drawing on a wealth of previously unused archival material, Medical Monopoly combines legal, medical, and business history to offer a sweeping new interpretation of the origins of the complex and often troubling relationship between the pharmaceutical industry and medical practice today. Joseph M. Gabriel provides the first detailed history of patent and trademark law as it relates to the nineteenth-century pharmaceutical industry as well as a unique interpretation of medical ethics, therapeutic reform, and the efforts to regulate the market in pharmaceuticals before World War I. His book will be of interest not only to historians of medicine and science and intellectual property scholars but also to anyone following contemporary debates about the pharmaceutical industry, the patenting of scientific discoveries, and the role of advertising in the marketplace.
For readers of Bad Blood and Empire of Pain, an authoritative look at monopoly medicine from the dawn of patents through the race for COVID-19 vaccines and how the privatization of public science has prioritized profits over people Owning the Sun tells the story of one of the most contentious fights in human history: the legal right to produce lifesaving medicines. Medical science began as a discipline geared toward the betterment of all human life, but the merging of research with intellectual property and the rise of the pharmaceutical industry warped and eventually undermined its ethical foundations. Since World War II, federally funded research has facilitated most major medical breakthroughs, yet these drugs are often wholly controlled by price-gouging corporations with growing international ambitions. Why does the U.S. government fund the development of medical science in the name of the public only to relinquish exclusive rights to drug companies, and how does such a system impoverish us, weaken our responses to crises, and, as in the cases of AIDS and COVID-19, put the world at risk? Outlining how generations of public health and science advocates have attempted to hold the line against Big Pharma and their allies in government, Alexander Zaitchik’s first-of-its-kind history documents the rise of privatized medicine in the United States and its subsequent globalization. From the controversial arrival of patent-wielding German drug firms in the late nineteenth century to present-day coordination between industry and philanthropic organizations—including the influential Bill & Melinda Gates Foundation—that stymie international efforts to vaccinate the world against COVID-19, Owning the Sun tells one of the most important and least understood histories of our time.
In contemporary global capitalism, the most powerful corporations are innovation or intellectual monopolies. The book’s unique perspective focuses on how private ownership and control of knowledge and data have become a major source of rent and power. The author explains how at the one pole, these corporations concentrate income, property and power in the United States, China, and in a handful of intellectual monopolies, particularly from digital and pharmaceutical industries, while at the other pole developing countries are left further behind. The book includes detailed empirical mappings of how intellectual monopolies develop and transform knowledge from universities and open-source collaborations into intangible assets. The result is a strategy that combines undermining the commons through privatization with harvesting from the same commons. The book ends with provoking reflections to tilt the scale against intellectual monopoly capitalism and arguing that desired changes require democratic mobilization of workers and citizens at large. This book represents one of the first attempts to capture the contours of an emerging new era where old perspectives lead us astray, and the old policy toolbox is hopelessly inadequate. This is true for the idea that the best, or only, way to promote innovation is to transform knowledge into private property. It is also true for anti-trust policies focusing exclusively on consumer prices. The formation of global infrastructures that lead to natural monopolies calls for public rather than private ownership. Scholars and professionals from the social sciences and humanities (in particular economics, sociology, political science, geography, educational science and science and technology studies) will enjoy a clear and all-embracing depiction of innovation dynamics in contemporary capitalism, with a particular focus on asymmetries between actors, regions and topics. In fact, its topical issue broadens the book’s scope to those curious about how innovation networks shape our world.
Continuing his pioneering theoretical explorations into the relationships among biosciences, the market, and political economy, Kaushik Sunder Rajan introduces the concept of pharmocracy to explain the structure and operation of the global hegemony of the multinational pharmaceutical industry. He reveals pharmocracy's logic in two case studies from contemporary India: the controversial introduction of an HPV vaccine in 2010, and the Indian Patent Office's denial of a patent for an anticancer drug in 2006 and ensuing legal battles. In each instance health was appropriated by capital and transformed from an embodied state of well-being into an abstract category made subject to capital's interests. These cases demonstrate the precarious situation in which pharmocracy places democracy, as India's accommodation of global pharmaceutical regulatory frameworks pits the interests of its citizens against those of international capital. Sunder Rajan's insights into this dynamic make clear the high stakes of pharmocracy's intersection with health, politics, and democracy.
The book studies the pharmaceutical industry of India. It is one of the most successful stories of economic expansion and improvements in public health. Indian firms have made access to quality medicines possible and affordable in many developing countries. Indian pharmaceuticals are also exported on a large scale to the United States and other highly regulated markets. A wave of mergers, acquisitions and tie-ups point to growing integration between Indian firms and global pharma multinationals. Please note: Taylor & Francis does not sell or distribute the Hardback in India, Pakistan, Nepal, Bhutan, Bangladesh and Sri Lanka
Controlling a major infectious disease outbreak or reducing rising rates of diabetes worldwide is not just about applying medical science. Protecting and promoting health is inherently a political endeavor that requires understanding of who gets what, where, and why. The Oxford Handbook of Global Health Politics presents the most comprehensive overview of how and why power lies at the heart of global health determinants and outcomes. The chapters are written by internationally recognized experts working at the intersection of politics and global health. The wide-ranging chapters provide key insights for understanding how advances in global health cannot be achieved without attention to political actors, processes, and outcomes.
Millions of people around the world do not have access to the medicines they need to treat disease or alleviate suffering. Strict patent regimes introduced following the establishment of the World Trade Organization in 1995 interfere with widespread access to medicines by creating monopolies that keep medicines prices well out of reach for many. 0The AIDS crisis in the late nineties brought access to medicines challenges to the public?s attention, when millions of people in developing countries died from an illness for which medicines existed, but were not available or affordable. Faced with an unprecedented health crisis ? 8,000 people dying daily ? the public health community launched an unprecedented global effort that eventually resulted in the large-scale availability of low-priced generic HIV medicines. 0But now, high prices of new medicines - for example, for cancer, tuberculosis and hepatitis C - are limiting access to treatment in low-, middle and high-income countries alike. Patent-based monopolies affect almost all medicines developed since 1995 in most countries, and global health policy is now at a critical juncture if the world is to avoid new access to medicines crises. 0This book discusses lessons learned from the HIV/AIDS crisis, and asks whether actions taken to extend access and save lives are exclusive to HIV or can be applied more broadly to new global access challenges.
Some two decades will shortly have passed since the WTO's Trade Related Aspects of Intellectual Property Rights agreement came into force in 1995. This volume is the first cross-country analysis of how TRIPS has affected the capacity of 11 major low or medium income countries to produce generic drugs.
Brazil has occupied a central role in the access to medicines movement, especially with respect to drugs used to treat those with the human immunodeficiency virus (HIV) that causes the acquired immune deficiency syndrome (AIDS). How and why Brazil succeeded in overcoming powerful political and economic interests, both at home and abroad, to roll-out and sustain treatment represents an intellectual puzzle. In this book, Matthew Flynn traces the numerous challenges Brazil faced in its efforts to provide essential medicines to all of its citizens. Using dependency theory, state theory, and moral underpinnings of markets, Flynn delves deeper into the salient factors contributing to Brazil’s successes and weaknesses, including control over technology, creation of political alliances, and instrumental use of normative frameworks and effectively explains the ability of countries to fulfill the prescription drug needs of its population versus the interests and operations of the global pharmaceutical industry Pharmaceutical Autonomy and Public Health in Latin America is one of the only books to provide an in-depth account of the challenges that a developing country, like Brazil, faces to fulfill public health objectives amidst increasing global economic integration and new international trade agreements. Scholars interested in public health issues, HIV/AIDS, and human rights, but also to social scientists interested in Latin America and international political economy will find this an original and thought provoking read.
